Teva Says Antitrust OK Just Months Away For $43B Mylan Deal
Generic-drug maker Teva Pharmaceuticals Industries Ltd. said Tuesday that its $43 billion takeover bid for rival Mylan NV could receive clearance from antitrust enforcers in as little as four months, in...To view the full article, register now.
Already a subscriber? Click here to view full article